Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Vir biotechnology, inc. save search
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -1.55%
H: 2.68%
C: 1.2%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2021-12-09 (Crawled : 14:30) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -1.69%
H: 6.48%
C: 2.62%
vir-2218 treatment phase 2 hepatitis technology trial biotech infection iot infections chronic hepatitis b nivolumab
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
Published: 2021-11-17 (Crawled : 12:00) - globenewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.43%
H: 2.31%
C: 2.27%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 9.97%
H: 4.0%
C: -6.28%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
covid treatment biotech technology iot covid-19
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.06%
H: 1.31%
C: 1.02%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.54%
H: 4.68%
C: 0.14%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 1.7%
C: 1.4%
covid treatment europe biotech technology iot covid-19
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.21%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.24%
H: 0.96%
C: -0.06%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.75%
H: 0.13%
C: -1.44%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.43%
H: 0.2%
C: 0.02%
covid treatment positive biotech technology iot ema
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
Published: 2021-05-07 (Crawled : 14:00) - biospace.com/
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.5%
H: 0.84%
C: 0.66%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.48%
H: 0.74%
C: 0.31%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 3.24%
H: 2.94%
C: 0.02%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
covid treatment biotech technology iot ema
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | News | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
Published: 2021-04-15 (Crawled : 14:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.23%
H: 1.59%
C: 0.08%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 0.37%
H: 2.8%
C: -1.49%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.76%
H: 0.61%
C: 0.14%
covid treatment antibody biotech technology iot ema
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published: 2021-03-26 (Crawled : 13:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.28%
H: 2.0%
C: 1.95%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.52%
H: 1.01%
C: 0.68%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.27%
H: 1.56%
C: -3.45%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.31%
H: 1.33%
C: 1.22%
covid treatment fda biotech technology iot merge submission authorized emergency use authorization
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
Published: 2021-03-11 (Crawled : 02:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.67%
H: 0.96%
C: 0.54%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.52%
H: 0.36%
C: -0.63%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 44.57%
H: 0.75%
C: -8.66%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.31%
H: 0.63%
C: 0.08%
covid treatment risk biotech iot
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Published: 2021-01-12 (Crawled : 08:03) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.29%
H: 0.21%
C: -0.95%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 1.91%
H: 16.28%
C: 11.28%
covid biotech treatment
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.